Inspire Medical Systems (NYSE:INSP) Shares Down 6% – Here’s What Happened

Inspire Medical Systems, Inc. (NYSE:INSP)’s stock price fell 6% during trading on Wednesday . The stock traded as low as $47.36 and last traded at $47.0710. 55,624 shares were traded during trading, a decline of 95% from the average session volume of 1,203,093 shares. The stock had previously closed at $50.08.

Analyst Upgrades and Downgrades

INSP has been the topic of several recent analyst reports. Bank of America cut Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a research note on Friday, May 22nd. Royal Bank Of Canada lowered Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research report on Monday, June 15th. Piper Sandler cut Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $85.00 to $55.00 in a report on Tuesday, May 5th. Truist Financial cut their price objective on Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a research report on Tuesday, May 5th. Finally, Evercore cut Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 target price on the stock. in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $81.05.

Inspire Medical Systems Trading Down 4.8%

The business’s 50 day moving average price is $44.31 and its two-hundred day moving average price is $61.08. The stock has a market cap of $1.37 billion, a P/E ratio of 10.64, a price-to-earnings-growth ratio of 5.01 and a beta of 0.71.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same period in the prior year, the firm earned $0.10 earnings per share. Inspire Medical Systems’s revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts expect that Inspire Medical Systems, Inc. will post 0.93 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after purchasing an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Inspire Medical Systems during the 1st quarter valued at $524,000. Goldman Sachs Group Inc. grew its position in shares of Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after buying an additional 18,857 shares during the period. Marshall Wace LLP grew its position in shares of Inspire Medical Systems by 3.8% in the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after buying an additional 577 shares during the period. Finally, Jump Financial LLC bought a new position in shares of Inspire Medical Systems in the 2nd quarter worth about $931,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.